Le Lézard
Classified in: Science and technology, Business
Subjects: VEN, CXP

Cardumen Capital raises $120 Million consolidating its position as one of Israel's most active early-stage Deep Tech investors


TEL AVIV, Israel, Jan. 17, 2024 /PRNewswire/ -- Israeli-European venture capital firm Cardumen Capital has successfully raised $120M for its second Deep Tech Fund, fortifying its commitment to nurturing early-stage Israeli startups.

Cardumen Capital has invested in 32 Israeli companies in AI, Cybersecurity, Big Data, and Information Communication Technologies (ICT). The company will continue investing in pre-seed and seed Israeli software and hardware companies at the forefront of the technological revolution.

Cardumen Capital aims to be the most active investor on the cap table. The company boasts an international Value Creation team that bridges the gap between international corporations and Israeli entrepreneurs. Cardumen Capital supports and works closely with entrepreneurs in anything from business development to fundraising. It's portfolio of exceptional entrepreneurs has a strong co-investor base such us as SaaS cybersecurity platform DoControl (backed by Insight Partners and Crowdstrike), Big Data B2G platform IVIX (backed by Insight Partners and Citi Ventures) or NeuReality (backed by Samsung and SK Hynix).

"Israeli entrepreneurs rise to the occasion under adversity", said Cardumen Capital's Co-Founder and General Partner, Gonzalo Martínez de Azagra. "It's in tough times when great companies are built. Our commitment to Israeli tech is stronger than ever. This commitment is reflected in our local team expansion. As a team of Israelis and Europeans, heavily connected with the US and Asian markets, we are well-positioned to give our startups access to worldwide markets. We look forward to partnering with entrepreneurs and our fellow investors in 2024 and beyond."

"We see a huge opportunity in the current market. We are actively deploying in what will probably be one of the best vintages of our generation," said Nimrod Brandt, Cardumen Capital's appointed Partner in Israel and an investment expert who has filled a number of executive roles at Hutchison, Gazit-Globe and Credit Suisse.

Cardumen Capital has also expanded its team over the past year with Nadav Charnilas (Principal), product and marketing veteran with over a decade of experience as a leader and operator at tech giants Microsoft, Vimeo, and Wix and Dana Kleiman (Associate), formerly Attorney at Israeli elite boutique Yigal Arnon & Co. The three have joined Noa Shamay (Principal) who has been with the firm for four years.

About Cardumen Capital

Cardumen Capital is a Venture Capital firm with offices in Tel Aviv and Madrid. Chaired by Gil Gidron and founded in 2018 together with Gonzalo Martínez de Azagra and Igor de la Sota, the company invests in early-stage DeepTech companies. Cardumen Capital has more than $225M under management and a team of professionals with a solid track record and more than a decade of experience investing in tech companies worldwide.

Contact:
[email protected]
Tel: +34 609 501 187

Photo: https://mma.prnewswire.com/media/2319532/Cardumen_Capital_team.jpg

SOURCE Cardumen Capital


These press releases may also interest you

at 20:49
TELUS Corporation (TELUS) announced today that the nominees listed in TELUS' 2024 information circular were elected as directors of TELUS. The detailed results of the vote for the election of directors held at TELUS' annual meeting on May 9, 2024...

at 20:20
A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National...

at 20:00
XTEND, the developer of XOS, an AI-driven operating system that is revolutionizing the way humans interact with drones and robots, today announced its $40M Series B round, led by Chartered Group, with...

at 19:41
Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be...

at 19:31
Reveald, an industry founder of Continuous Threat Exposure Management, has expanded its capabilities by acquiring rThreat and creating the Epiphany Validation Engine (EVE) to enhance AI-driven cyber resilience. EVE is a state-of-the-art emulation...

at 19:30
Rakuten Medical, Inc., a global...



News published on and distributed by: